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ABSTRACT
Percutaneous ablation is an increasingly applied technique for the treatment of localized renal tumors,
especially for elderly or co-morbid patients, where co-morbidities increase the risk of traditional neph-
rectomy. Ablative techniques are technically suited for the treatment of tumors generally not exceed-
ing 4 cm, which has been set as general consensus cutoff and is described as the upper threshold of
T1a kidney tumors. This threshold cutoff is being challenged, but with still limited evidence.
Percutaneous ablation techniques for the treatment of renal cell carcinoma (RCC) include radiofre-
quency ablation, cryoablation, laser or microwave ablation; the main advantage of all these techniques
over surgery is less invasiveness, lower complication rates and better patient tolerability. Currently,
international guidelines recommend percutaneous ablation either as intervention for frail patients or
as a first line tool, provided that the tumor can be radically ablated. The purpose of this article is to
describe the basic concepts of percutaneous ablation in the treatment of RCC. Controversies concern-
ing techniques and products and the need for patient-centered tailored approaches during selection
among the different techniques available will be discussed.
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Introduction
Ablation used to treat kidney tumors was first described as
being a novel technique in the early 80s when absolute
ethanol was injected directly into the tumoral vasculature
[1]. In parallel to the advent of chemical ablation, techno-
logical evolution offered its alternatives to surgery with par-
ticular emphasis on thermal based ablative tools such as
focused ultrasound, laser, cryo-therapy and radiofrequency
(RF). The latter techniques, in particular, have become popu-
lar in the past 20 years. The most recent evolution of abla-
tive techniques to treat renal tumors nowadays includes
microwave (MW), irreversible electroporation and radiosur-
gery. The main advantage of all these techniques over sur-
gery is less invasiveness and better patient tolerability,
especially if performed percutaneously. Yet if technical con-
traindications hamper percutaneous access, ablation can be
performed intra-operatively and allows for maximized paren-
chymal sparing [2].
According to the GLOBOCAN 2018 statistics, kidney can-
cer’s incidence is 8th among cancers in Europe with more
than 130,000 new cases and more than 54,000 deaths per
year. Early detection and detection due to incidental imaging
findings has led to an increased interest in alternatives to
surgical resection to treat small sized tumors such as percu-
taneous ablation. Small renal masses (SRMs) encompass a
wide range of benign and malignant tumors and are defined
by having a size less than or equal to 4 cm [3]. Although in
most of the cases, the masses are confirmed as being renal
cell carcinomas (RCCs), up to 25% are benign renal cortical
tumors (i.e., oncocytoma, atypical angiomyolipoma) and
another 25% are diagnosed as masses with limited meta-
static potential [3]. Historically, surgical resection is the
standard of care for the treatment of localized renal tumors
and partial nephrectomy has been labeled superior to radical
nephrectomy for T1 tumors, in terms of long-term renal func-
tion and overall survival, while maintaining equivalent onco-
logic outcomes [3].
Ablative techniques are technically suited for the treat-
ment of tumors generally not exceeding 4 cm, which has
been set as general consensus cutoff and is described as the
upper threshold of T1a kidney tumors [4]. This threshold cut-
off is being challenged, but with still limited evidence [5].
Although not yet established as routine technique, renal
tumor biopsy should always be considered to confirm or rule
out malignancy [3,6]. One of the major concerns in the use
of ablation regards the lack of definitive histopathology of
the ablated lesion, which contributes to determining patient
prognosis. While intra-intervention biopsy should be standar-
dized, strict imaging follow-up is strongly recommended in
this setting in order compensate this potential limitation [7].
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Compared to surgery, thermal ablation has been shown to
have a lower rate of complication, shorter recovery and add-
itionally spares renal parenchyma. Documented, dated and
probably biased data due to non-uniform patient popula-
tions, differences in techniques and retrospective nature
reported the risk of a higher local recurrence rate [3].
Inadequate percutaneous access or coagulopathies which
cannot be corrected, in addition to lesion size, are the main
technical and clinical contraindications of thermal ablation.
With the use of ablation, though, target lesion proximity to
noble structures (i.e., renal pelvis, ureter, adjacent bowel) can
be easily overcome by technical tricks [2,8].
The purpose of this article is to describe the basic con-
cepts of percutaneous ablation in the treatment of RCC.
Controversies concerning techniques and products will be
addressed. The necessity for an individually tailored approach
for the selection of the different techniques and targets will
be emphasized.
Patient selection
All cases should be discussed within a multidisciplinary
tumor board composed by at least an interventional radiolo-
gist, an urologist and an oncologist, as per current guidelines
[9]. The ideal candidate for renal tumor ablation is a patient
that presents a T1a (4 cm) RCC, with contraindications or
unwillingness to undergo surgery and with any grade of
impairment of renal function. Though pathognomonic fea-
tures of malignancy at imaging are evident, as detailed previ-
ously, pre-ablation biopsy is strongly recommended [9].
Since percutaneous ablation in general clinical practice is
performed with moderate sedation (not general anesthesia),
impairment of lung function or other relative contraindica-
tions to surgery, are not patient exclusion criteria. However,
in case of absolute contraindications to surgery (i.e., coagulo-
pathies), percutaneous ablation should be considered with
caution [10].
If pathognomonic features of malignancy at imaging stud-
ies are not present but the mass has increased over time,
treatment may be justified. In this particular scenario, a pre-
interventional percutaneous needle biopsy is cardinal; if
biopsy fails to prove malignancy (e.g., uncertainty between
oncocytoma and chromophobe tumor), percutaneous abla-
tion could be the first choice of intervention, due to its
minor invasiveness respect to surgery. Additional ideal candi-
dates for percutaneous renal ablation are those who have
already undergone tumor enucleation, partial- or complete-
nephrectomy, for who renal function impairment is very
likely and parenchymal sparing is crucial. This group of
patients is generally affected by genetic syndromes (i.e., Von
Hippel Lindau) that develop multiple renal tumors during
the course of their life.
A case-to-case evaluation, based on each individual set-
ting, and pre-interventional imaging interpretation, is key in
order to identify potential technical contraindications and
plan fine tuning where needed.
Ablation modalities
Various ablative techniques have been applied for the treat-
ment of renal tumors, including RF, MW, laser and cryoabla-
tion (CA) [11]. The majority of available literature comes from
the experience with RF and CA, but MW is recently gaining
more importance due to its higher availability and its intrin-
sic features. RF ablation (RFA) is delivered through high-
frequency alternating current (460–500 kHz) via an RF elec-
trode (available in a great number of shapes and sizes)
resulting in ionic agitation which causes frictional heat (tem-
peratures of 60–100 C) (Figure 1). When temperatures reach
50 C cellular destruction commences, followed by protein
denaturation and finally coagulative necrosis (of tumoral tis-
sue). Gas formation (100 C) represents the main limitation
for a potential increase of temperature [12]. Microwave
energy exerts its effect through dielectric hysteresis and
water molecules agitation. Microwave generators have over-
come the gas formation limitation by operating at 915MHz
to 2.45GHz. Advantages of MW over RFA include the ability
to achieve higher temperatures (over 100 C) less affected by
‘heat-sink’ effect caused by the blood stream and any kind
of impedance-driven performance producing larger ablation
volumes in shorter time; other advantages include less pro-
cedural pain and lack of a need for grounding pads place-
ment (Figure 2) [13]. Photoablation/laser ablation has been
successfully applied in the treatment of benign and malig-
nant diseases, including the treatment of renal tumors. A col-
limated, coherent, monochromatic light beam is delivered
through a small, precise optical fiber which interacts with
biological tissues which determines the focal increase in tem-
perature (Figure 3) [10]. Cryoablation is another well-
established technique for renal ablation. The depressurization
of a cryogen gas, such as argon, causes a fast decrease in
temperature at the tip of an antenna (–160 C or colder),
which by passive thermal diffusion acts on the tumor. Slow
and fast freezing produces intracellular and extracellular
crystals, respectively (Figure 4). A process of subsequent
freeze-thawing cycles causes cell death through cellular
dehydration, vascular thrombosis and membrane rupture
[14]. Cryoablation is governed by specific advantages includ-
ing visibility of the ice-ball and the ability to produce a
large-sized ablation zone that can be geometrically designed
facilitating a reproducible and predictable ablation shape (by
simultaneous use of multiple probes) with minimum patient’s
pain and discomfort; all these come in increased cost and
time duration.
Image-guidance for ablation
RCC ablation is assisted by state-of-the art imaging. US
remains the most frequently used and available imaging
method to guide renal ablation and assess technical success
in certain cases with the aid of US contrast-medium adminis-
tration (CEUS) [15–18]. Moreover, US has the priceless advan-
tage to provide real-time image guidance, which is
extremely useful to follow each step of the tumor ablation
procedure. Conversely, US is limited by inherent patient and
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characteristics and gas formation limits a proper visualization
of the ablation area, making post-procedural assessment dif-
ficult [15–18]. Limitations are linked to patient and tumor
conformation as well as proper visualization of the ablation
zones post-procedure or due to gas. Isoechoic tumors or
tumors located in deep regions may also be difficult to visu-
alize [15–18].
CT and the more recent CBCT, provide a larger field of
view, are less limited by the patient structure or body region,
and can provide an easier post-procedural assessment, espe-
cially after contrast-medium administration [16]. However,
both CT and CBCT require radiation exposure and high oper-
ator experience to guide non-axial approaches. MR, due to
its characteristics, may see to represent an ideal imaging aid,
since it lacks ionizing radiation, provides for good anatomical
definition as well as real time visualization of the procedure.
MR guidance for ablation, though, requires a complex envir-
onment and its use is limited to a few highly specialized cen-
ters [9]. Finally, PET/CT has the advantage of merging
anatomical and functional information, and has been pro-
posed as a valid alternative in certain interventional proce-
dures in which lesions are poorly visible at conventional
imaging [19,20]. In recent years, real time fusion of multiple
imaging modalities has been implemented and successfully
applied in the guidance of tumor ablation [15–20]. This strat-
egy is highly promising, since it merges advantages of differ-
ent imaging modalities succumbing their limitations,
allowing performance of a successfully ablation even of com-
plex lesions without a relevant increase in the operatory
environment complexity [15–20].
Ablation procedure
Different crucial steps lead to successful ablations; planning,
targeting, monitoring and result assessment. A personalized
treatment planning including careful choice of the best abla-
tion modality, patient positioning, image-guidance and type
of anesthesia is critical to achieve a successful procedure and
avoid complications. In this perspective, practical algorithms
for procedure planning have been proposed, such as the
ABLATE approach (A, axial tumor diameter; B, bowel proxim-
ity; L, location within the kidney; A, adjacency to the ureter;
T, touching renal sinus fat; and E, endophytic or exophytic
position) [21]. Particularly important is the diameter of the
tumor, directly related to ablation success and bleeding risk
[22,23]. After a careful case-to-case evaluation, planning the
procedure includes also identifying the ideal anesthesiologic
regimen for the procedure. Several technical aspects should
be considered for a successful renal ablation, from patient
positioning, to the need of stent insertion for pyeloperfusion
or need for hydro or pneumo-dissection to protect surround-
ing critical structures [24]. Proper ablation needs to also con-
sider protective techniques aimed at reducing damage to
adjacent structures. Saline hydrodissection and CO2
Figure 1. RFA of a right renal tumor adjacent to the right colon. Before the treatment, hydrodissection has been obtained in order to reduce the risk of bowel
damage and perforation. (A) Contrast-enhanced CT demonstrating the enhancing tumor in the right kidney (white arrows). (B–D) A spinal needle has been inserted
and dextrose 5% has been infused for hydrodissection. (E) An umbrella-like RF electrode has been inserted in the lesion. (F) Post ablation necrotic zone (white
arrows) has covered the whole lesion with no damage to the adjacent colon.
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insufflation are two commonly used to isolate the kidney
during the ablation, but sometimes just a proper patient
positioning aided by vacuum mattress can be sufficient to
displace surrounding structures. In addition, a slight traction
of the electrode, known as ‘torqueing’, can be applied during
ablation. When the excretory system is at risk for damage,
cold pyeloperfusion can be performed through a ureteral sin-
gle J connected to a cold fluid bag [19]. For a proper tumor
targeting, the ideal image guidance method should be care-
fully chosen.
Once the chosen device has been properly inserted in the
target tumor, ablation must be monitored thoroughly to
assess ablation technical success and monitor potential com-
plications. Real time US can show early signs of complete
ablation, coverage of the target tumor by hyperechoic area
due to gas formation, and early bleeding. Once the ablation
is completed, contrast-enhanced imaging such as CEUS and/
or contrast-enhanced CT can provide more precise informa-
tion regarding the completeness of ablation, and eventually
guide further treatment in the same operative session [25].
Advantages of MRI peri-operative control include the tumor
visibility without the need for contrast medium injection, the
ability of multiplanar, near-real time advancement of the
probe toward the target and the lack of ionizing radi-
ation [26].
Clinical outcomes
Regardless the technique used, clinical outcomes are invari-
ably associated with dimensions of the renal tumor.
Ablations of T1a (4 cm) lesions show technical success
approaching 100% and excellent primary local control. In a
recent paper, Talenfeld et al. evaluated retrospectively T1a
lesions treated either with RF-, cryo- or MW ablation report-
ing similar outcomes of total or partial nephrectomy (5-year
cancer-specific survival 95–98%), but observing less peripro-
cedural complications, less unplanned hospital readmissions,
reduced 30- and 90-day mortality and a lower risk of long-
term renal insufficiency [27]. Another recent retrospective
analysis performed on a large patient cohort with long-term
follow up confirmed 3-, 5- and 9-year specific and nonspe-
cific cancer survival rates not to be statistically significant
Figure 2. MWA of renal cell carcinoma (biopsy proven) located in the apex of the left kidney. (A) T1-weighted fat saturated sequence post IV contrast medium
injection depicting the lesion (arrow) in the apex of the left kidney. (B) Patient was placed in lateral decubitus position – a microwave antenna was inserted and
ablation session was performed according to the provided dimensions on terms of energy (W) and time (min). (C, D) Computed tomography scans in arterial (C)
and venous (D) phases illustrating complete tumor ablation (arrow).
24 D. FILIPPIADIS ET AL.
among thermal ablation, partial and total nephrectomy [28].
These recent insights, along with detailed economic analysis
supporting the convenience of minimally invasive procedures
have been confirmed in numerous studies, including recent
meta-analysis [22,23,29–31]. Within the T1a classification,
tumors larger than 3 cm have been associated with higher
incidence of recurrence, with a disease-free survival of 68%
compared to 97% of tumors 3 cm [32]. Even though sur-
vival rates are comparable between RF, cryo- and MW abla-
tion, MW ablation has achieved shorter procedural times and
required less sedation than cryo- and RFA. However, no com-
pelling evidence suggest that one technique is superior to
any of the other [9,22,27].
For T1b lesions (7 cm), 5-year overall survival rates were
similar in a recent study comparing RFA and CA (78% vs.
82%), even though CA was associated with higher primary
technical efficacy (65% vs. 95%) [5]. Radiofrequency ablation
achieved notable results when compared to partial nephrec-
tomy, with a 5-year overall survival of 85.5% vs. 96.6%, a
5-year cancer-specific survival of 92.6 vs. 96.6% and a 5-year
disease-free-survival of 81.0% vs. 89.7% [33]. In a small
patient sample, MW ablation achieved excellent primary effi-
cacy in lesions >4 cm with no local tumor progression after
1-year follow-up [34]. In addition to careful patient selection
and the availability of state-of-the art image-guidance, the
interventional radiologist’s experience must be considered
and most-likely still represents the fundamental element in
order to achieve excellent results [35].
Complications
Reported complications include renal infection, hemorrhage,
pneumothorax, thermal damage to surrounding structures
(ureter, bowel, genitofemoral nerve, psoas muscle) and track
seeding [36,37]. Most commonly, complications post-percu-
taneous ablation of renal masses are associated to bleeding
or non-target thermal injury; hematoma formation rate is
6% while that of massive bleeding requiring transfusion is
<1% [9]. Post-ablation syndrome is an accepted, self-limiting
condition occurring in about 9% of patients; a combination
of fever and flu-like symptoms (myalgia, malaise, mild pain
at the site of ablation) should not be considered as a compli-
cation but as an expected side effect [38,39]. Complications
are assessed through standard classifications scales such as
the revised Clavien–Dindo classification [40] and proposed
scores by the main radiological societies [41,42]. 13–17% are
classified as minor complications and 1.8–6% major compli-
cations, which require non-medical therapy [5,43,44].
Cumulative 30-day non-urologic complication rate has been
reported to be 6% for patients treated with percutaneous
Figure 3. Patient with previous right nephrectomy for RCC who developed a small 9mm new lesion in the left kidney and was successfully ablated with image
guided laser ablation. (A) Contrast-enhanced CT demonstrating a 9mm posterior enhancing tumor (arrow) in the left kidney. (B) Ultrasound scan demonstrating
the left kidney lesion (arrow). (C) Ultrasound scan demonstrating the positioning of the tip of the laser fiber in the middle of the lesion to be treated (arrow). (D)
Ultrasound scan demonstrating hyperechoic area due to gas formation during treatment (arrows). (E) Contrast-enhanced ultrasound demonstrating the absence of
enhancement at the level of the treated lesion (arrows). (F) Contrast-enhanced MRI at 3 months demonstrating the complete treatment of the renal lesion
(arrows¼ ablative area).
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ablation vs. 29–30% for patients treated with partial or total
nephrectomy. Rates of acute renal failure were found to be
lower for percutaneous ablation (3% vs. 7–11%) [27,45].
Meta-analytic pooled incidences concerning major and minor
complications of MW ablation reported rates of 1.8% and
17.5%, respectively [30].
Controversies
Comparing different ablation techniques
In current clinical practice, the most often used percutaneous
ablation techniques are RFA and CA while microwave abla-
tion (MWA) is increasingly being used in the treatment of
RCC [9]. Percutaneous irreversible electroporation is a new
emerging focal ablation technique but there is limited
experience in its use for RCC treatment and high intensity
focused ultrasound is used in experimental settings [10,46].
Each technique has advantages and disadvantages that have
to be considered by the interventional radiologist in each
particular setting to achieve best patient outcome. In litera-
ture, no randomized prospective clinical trials have compared
different ablation techniques for treatment of RCC [47].
Radiofrequency ablation and CA are the techniques that are
advised by current guidelines and are considered equivalent
as they both have excellent technical success rates and low
tumor recurrence rates (even in cases of repeated ablation)
[8,10,48]. Evidence in literature suggests that there are no
significant outcome differences regarding overall complica-
tions, metastasis-free rates and cancer-specific survival
Figure 4. Percutaneous cryoablation of renal clear cell tumor of the right kidney. (A) Arterial phase contrast-enhanced CT (supine position) shows a hypervascular
lesion (arrow) in the medial mesorenal region of the right kidney. (B) Same tumor presented in image (a) two cryoablation probes are inserted within the tumor
through a posterior retroperitoneal approach. (C) Arterial phase contrast-enhanced CT (supine position) shows a gross hypervascular lesion, which demonstrated to
be a clear cell tumor (arrow) in the lower pole of the right kidney. (D) 7mm-MIP axial reconstruction shows three cryoablation probes positioned within the tumor
through a postero-lateral retroperitoneal approach. (E) Same lesion presented in images C and D: sagittal reconstruction shows the three probes oriented in three
different planes (arrow) of space in order to shape the ice ball in the three dimensions.
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between RFA and CA [8,23]. In comparison to CA, RFA costs
less, procedure time is shorter and bleeding complication
rate is lower, yet CA is less harmful to the renal collecting
system [46,49,50]. Microwave-based techniques present prac-
tical advantages over radiofrequencies, but their more recent
development is coupled with limited literature compared to
RFA and CA, i.e., lack of mid- and long-term follow-up and
RCT [12,51]. Available evidence on MWA in renal tumors sug-
gests that MWA has a similar or slightly better technical effi-
cacy rate and local tumor recurrence rate than RFA or CA
with comparable complications rates and lower incidence of
major complications [30]. In comparison to RFA, MWA pro-
cedure times are shorter and the procedure is less influenced
by the heat-sink effect also providing larger ablation zones
[43,46,51]. Advantages of CA include the ability to monitor
ablation with imaging, the potential treatment of T1b RCCs
and the treatment of centrally located or very close to vul-
nerable structures, such as the spinal column and the bowel,
RCCs [46,52,53].
Percutaneous ablation vs. surgery or active surveillance
The gold standard of treatment of small RCCs remains surgi-
cal resection (radical or partial nephrectomy) but percutan-
eous ablation is a solid-based alternative technique for the
treatment of small RCCs showing comparable oncological
outcome results to partial nephrectomy and minimal risk of
severe complications [45,54]. In the literature, there is only
one randomized controlled trial (RCT) with a small number
of patients comparing partial nephrectomy and MWA and
there is no level 1 evidence regarding the comparison of the
different ablation techniques with surgery for stage T1a
RCC [55,56].
Thermal ablation, on contrary to surgery can be per-
formed without the need of general anesthesia and is a
nephron-sparing technique facilitating preservation of renal
function similar to partial nephrectomy [57]. Published data
have shown that major complication rates were significantly
lower or similar in thermal ablation treatment compared to
partial nephrectomy and overall lower complication rates fol-
lowing thermal ablation [22,58,59]. MWA was shown to have
significantly fewer complications and less blood loss than
partial nephrectomy and is considered to be as safe as RFA
in RCC treatment [55,56]. Deterioration of renal function has
been shown to be significantly greater in case of surgery
than in case of ablation techniques in many published stud-
ies suggesting the feasibility of ablation treatment in patients
with impaired baseline renal function [22,60].
Thermal ablation exhibits metastasis-free and cancer-spe-
cific survival rates comparable to surgery [23,57]. Published
data have shown that local recurrence-free survival was
worse for thermal ablation than surgery but secondary effi-
cacy of thermal ablation (repeat ablation) showed no differ-
ence compared with surgery [23]. Oncologic outcomes
diminish as RCC’s size exceeds 3 cm in diameter [31,61].
Comparison of MWA with partial nephrectomy revealed simi-
lar relapse-free survival and cancer-specific survival rates [55].
Ablation techniques have been shown to be more
cost-effective than partial nephrectomy due to their minimal-
invasive approach and less cost and procedure time [58,62].
In Clinicaltrials.gov using search parameters ‘percutaneous
ablation’, only three completed studies are available in which
renal masses were ablated using the percutaneous approach.
The CONSERVE trial, a feasibility, multicenter RCT comparing
surgery to needle ablation techniques in patients with SRMs
(4 cm) was concluded in 2015 but results were never pub-
lished. Results still lack for other two registered studies: the
RF-REIN trial, which evaluated the efficacy of RF in the treat-
ment of renal tumors in which 310 patients were enrolled,
and the CRYOREIN trial, which evaluated the efficacy of per-
cutaneous CA for renal tumors <4 cm in patients not candi-
dates for partial nephrectomy, respectively, indicated as
concluded in 2015 and 2016. Concerning intra-operative
ablation, a large multi-institutional European registry
(EURECA) which involved 808 patients with T1a RCC treated
with laparoscopic-assisted CA, revealed satisfactory long-term
oncological outcomes in a non-direct comparison with surgi-
cal resection [2].
Another interesting topic to consider is the comparison
between active surveillance and ablation: a randomized,
feasibility trial comparing ablation vs. active surveillance
(SURAB) concluded that the hypothesized recruitment rate
was lower than expected and therefore the criteria for dis-
ease progression were not met and demonstrated that the
times were not mature for conducting and completing such
a trial [63]. Active surveillance trials and potentially programs
could lead to a better and broadened view of the actual
behavior of small renal tumors, yet not clearly understood.
Recent guidelines
Percutaneous ablation for RCC is considered as a treatment
alternative to partial nephrectomy and is advised by various
published guidelines. In 2015, the European Association of
Urology published guidelines stating that thermal ablation is
indicated in case of small RCCs in elderly patients with co-
morbidities considered unfit for surgical treatment, patients
with a genetic predisposition to develop multiple tumors
and patients with bilateral tumors or with a solitary kidney
and a high risk of complete loss of renal function following
partial nephrectomy [64]. It was also stated that due to the
quality of the available data (level of evidence 3) no definite
conclusions could be reached regarding morbidity and onco-
logical outcomes for RFA and CA [64].
The National Comprehensive Cancer Network (NCCN)
Clinical Practice guidelines in oncology published in 2017,
stated that ablative techniques can be considered only in
selected patients with clinical stage T1a RCCs, are associated
with a higher local recurrence rate than conventional surgery
and also highlighted the lack of a randomized phase III com-
parison of ablative techniques with surgery [48]. The guide-
lines also stated that biopsy may be considered to obtain or
confirm a diagnosis of malignancy and guide surveillance
and ablation [48].
The 2017 American Society for Clinical Oncology (ASCO)
guidelines on the management of small RCCs stated that
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percutaneous thermal ablation should be considered for
patients with tumors that are located such that complete
ablation can be achieved and TA should be reserved for
carefully selected and counseled patients [3]. This recommen-
dation was supported by intermediate quality evidence and
was considered to have a moderate strength [3]. Biopsy is
recommended prior or at the time of ablation in order to
guide surveillance [3].
In 2017, the American Urological Association (AUA) pub-
lished updated guidelines stating that thermal ablation
should be considered as an alternate approach for manage-
ment of cT1a renal masses <3 cm in diameter and a percu-
taneous approach is preferred [8]. The guidelines suggested
that RFA and CA are equivalent and have similar oncologic
efficacy [8]. The above recommendations were supported by
grade C evidence [8]. It was also stated that a renal mass
biopsy should be performed prior to ablation for diagnostic
purposes and to guide surveillance and a strong recommen-
dation (evidence level grade B) was made regarding counsel-
ing about thermal ablation that should include information
about an increased likelihood of tumor persistence or local
recurrence after primary ablation which may be addressed
with repeat ablation if further intervention is elected [8].
As the level and quality of evidence regarding percutan-
eous ablation techniques remains low, and this is stated in
the aforementioned guidelines, there is need for level 1 data
comparing the available treatment strategies for small RCCs
to clearly establish the role of thermal ablation in the man-
agement of these tumors. The main concern which has ham-
pered the widespread adoption of thermal ablation to treat
renal tumors is the lack of data proving sustained onco-
logical efficacy. The absence of RCTs, the heterogeneity of
patient populations investigated, indications, histopathology
and methods described in the literature do not consistently
provide for the above. However, in the past couple of years,
literature has been laden with substantiated intermediate
and long-term follow-up data; reviews and series, mainly
from retrospective observational studies in which thermal
ablation, mainly RFA and CA, is compared to surgery still
considered gold-standard [12,24,52,58,65–68]. In addition,
percutaneous thermal based techniques are compared to
surgery (nephrectomy, partial nephrectomy), to laparoscopy
and among themselves [27,69–76]. The most recent
European Society of Medical Oncology (ESMO) guidelines
suggest that percutaneous ablation techniques (incl. RFA,
MWA and CWA) are options for patients with small
cortical tumors <3 cm in diameter especially in cases of
co-morbidities [77].
Conclusions
Percutaneous ablation of RCC is a safe and efficacious tech-
nique for the treatment of T1a renal masses. As size grows
larger than 4 cm in T1b tumors addition of trans-arterial
embolization can be suggested in order to enhance percu-
taneous ablation. Percutaneous ablation procedures for the
treatment of RCC are low cost, of short duration of hospital-
ization with low complication rates when compared to
surgical approaches. Further evaluation of the technique
against surgical therapies in a comparative randomized
mode is warranted.
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